View metadata, citation and similar papers at core.ac.uk

brought to you by CORE

provided by IntechOpen

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

4,800
Open access books available

122,000
International authors and editors

135M
Downloads

Our authors are among the

154
Countries delivered to

TOP 1%
most cited scientists

12.2%
Contributors from top 500 universities

CLARIVATE ANALYTICS BOOK CITATION INDEX INDEXED

WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

9

Pharmacogenetics of Asthma

Andrzej Mariusz Fal and Marta Rosiek-Biegus
Wroclaw Medical University, Wroclaw, Poland

1. Introduction

Pharmacogenetics uses genetic information to help adjusting treatment for individual patients. It improves efficacy of therapy and enables avoiding side effects basing on genetic knowledge. Different asthmatic patients with similar disease severity, who are treated with the same medication, may respond to the therapy differently. After excluding non-genetic causes of such variability (like patient's compliance, environmental and psychological factors), the most possible reason for the variability appears to be a different genetic structure. Changes in gene structure resulting in inter-individual dissimilarities, occur mostly as single nucleotide polymorphism (SNP). Different strategies play a role in searching and identifying SNPs, that influence pathogenesis of asthma and its response to treatment, (Kazani et al., 2010). One of the strategies involved is candidate gene studying, that focuses on finding genes responsible for therapy effectiveness as well as asthma development and its clinical severity (Moffatt & Cookson, 1997). Pharmacogenetics of asthma concentrates on genes coding: drug binding receptors, enzymes (important both in drug metabolism and metabolic cycles, eg. arachidonic acid cascade), chemokines, cytokines or growth factors relevant to asthma pathogenesis and pathophysiology. Genes need to be studied for known SNPs and new variants as well. When an SNP is found a thorough check for possible correlation between this polymorphism and disease phenotype or treatment response is needed. An expanded strategy for searching candidate genes involves screening of genes encoding proteins (enzymes) active in metabolic cycles important for drug response or key disease pathologies. In asthmatic patients this last method is often used to examine the leukotriene pathway in order to elucidate different patient reactions to leukotriene modifiers. Other options are genome-wide association studies that analyze genetic markers across the entire genome that may be connected with the phenotype. The identification of such a marker generated investigation of surrounding genes for SNPs related to the phenotype (Kazani et al., 2010). This procedure needs numerous and phenotypically well characterised populations and enables examination of the most frequent SNPs. There are some fields of medicine where pharmacogenetics is already in clinical use but in asthma treatment further investigation is still needed. This chapter reviews recent knowledge of pharmacogenetics of drugs commonly used in asthma treatment. We focus on bronchodilators, iCS (inhaled corticosteroids) and leukotriene modifiers.

2. Pharmacogenetics of antiasthmatic medications

2.1 Pharmacogenetics of β2-agonists

β2-adrenoreceptor (β2-ADR) agonists are fundamental relief medications and among the most important chronic treatments in asthma. These drugs exert their action by activation of β2-adrenoreceptors located among others on smooth muscle cells. This results in smooth muscle relaxation, airway dilatation and improved airflow. Depending on the duration of their action β2-agonistss are divided into two groups: short acting (SABA) and long acting β2-agonists (LABA). SABA are used exclusively as rescue medicines. They quickly reduce asthma symptoms: wheezing, shortness of breath and coughing. While LABA when used on a daily basis in combination with iCS help to improve asthma control. The side effects are common for both groups and these are: tachycardia, muscle tremble, mild hypokalaemia.

The β2-adrenoreceptor is a member of the 7-transmembrane domain G-protein coupled receptor family. It consists of seven transmembrane spanning domains, 3 extracellular and 3 intracellular (Fig. 1) (Dixon et al., 1986). Stimulation of β2-adrenoreceptor is G-protein dependent and results in activation of the second messenger, the adenylate cyclase. This in turn leads to an increase of cAMP level and smooth muscle relaxation. Another mechanism resulting from β2-adrenoreceptor stimulation is potassium channels opening by cAMP or directly by G-protein (Kowalski & Woszczek, 2002).



Fig. 1. Most common clinically relevant polymorphisms of the β2-adrenoreceptor (Ligget, 1997-changed). Black - nucleic acid deviations from wild type not resulting in nucleotide changes.

2.1.1 Polymorphisms of the β2-adrenergic receptor

Examination of the intronless β2-adrenoreceptor gene, which is located on chromosome 5q31.32 (Kobilka et al., 1987), revealed over 80 SPNs (Weiss et al., 2006). Two of these polymorphisms: Arg→Gly16 (46A→G) and Gln→Glu27 (79C→G) are the most frequent ones (see Figure 1.) (Green et al.,1994, 1995; Lee et al., 2004). Their occurrence results in receptor function change, different ligand binding and impaired signal transmission. The occurrence of the Gly16 gene variant is higher than that of the wild-type Arg16 and ranges between 67% in British asthmatics and 72% in British and American healthy subjects (Liggett, 1997; Tan et al., 1997; Lipworth et al., 1999). It has been estimated that the homozygous genotype Arg16 appears in 16% Caucasians and 25% Afro-Americans. Studies of Xie (Xie, et al., 2001) and co-workers revealed further differences between β2-adrenoreceptor polymorphisms and ethnic groups. In a study, that examined 415 healthy subjects, Glu27 allele were the most frequent in Caucasian-Americans (34.8%). Other groups had much lower occurrence of this allele: Afro-Americans (20.7%) and Chinese (7.2%). Individuals with homozygous Glu27 genotype were mostly Caucasian-Americans (15.4%). This genotype occured only in 4.9% African-Americans and was not observed in Chinese subjects (Xie, et al., 2001). Both Gly16 and Glu27 polymorphisms are involved in higher agonist promoted receptor down-regulation, moreover, Glu27 is related with a stronger desensitization of the receptor (Green et al., 1994, 1995). Another defined polymorphism: Thr→Ile164 is associated with diminished affinity of β2-agonist to the receptor, decreased adenylate cyclase binding and 50% shorter lasting salmeterol (one of the long acting beta2 agonists) effect (Green et al., 2001).

2.1.1.1 Correlation between β2-adrenoreceptor gene polymorphism and short acting β-agonists action

Short acting β-agonists are drugs commonly used in asthma treatment, especially in asthma exacerbations or as regular rescue medications. However, they are not recommended as regular antiasthmatic drugs. Several studies demonstrated higher FEV1 increase (forced expiratory volume in the first second, a spirometric parameter used to determine the level of airways narrowing) increase after SABA (salbutamol) administration in homozygous Arg16 individuals as compared to heterozygous and homozygous Gly16 patients with polynosis (Martinez et al., 1997; Woszczek et al., 2005). Different results were obtained during asthma exacerbation. Patients who were homozygous Arg16 had impaired SABA response compared to homozygous Gly16 individuals (Carroll et al., 2009). Systematic administration of SABA to Arg16 asthmatics caused deterioration of lung function (as evaluated with PEF - peak expiratory flow, another parameter used to monitor airway narrowing), that did not stop even with treatment discontinuation. In contrast patients homozygous for Gly16 demonstrated improved lung function (evaluated by PEF measurement as well) (Israel, 2000, 2004). Based on these studies it has been postulated that Arg16 homozygotes may be at higher risk during long-term SABA therapy. According to the 2010 updated GINA guidelines (Global Initiative for Asthma [GINA], 2010) regular long-term SABA treatment is not recommended for any individual. But due to relatively low differences in PEF-worsening between the two groups more research is needed to fully elucidate this problem.

2.1.1.2 Correlation between β2-adrenoreceptor gene polymorphisms and long acting β-agonists action

Long acting β2-agonists as opposed to SABA are drugs commonly used in long-term asthma therapy. There are several population studies suggesting increased risk of therapy with long acting β2-agonists in patients with the Arg16 homozygous genotype. However, no genotype is currently considered a direct contraindication for LABA treatment. Some patients treated with salmeterol, experienced rare but severe asthma exacerbations (Nelson et al., 2006). Further investigation suggested a dependence between Arg16 genotype and faster decline of lung parameters (FEV1) after LABA application (Nelson et al., 2006; Wechsler et al., 2006; Lee et al., 2004; Palmer et al., 2006). A good example is a study of Wechsler and co-workers comparing salmeterol response in individuals with asthma homozygous for arginine (Arg16) with glycine homozygous (Gly16) group of patients. Patients were divided in two groups . The first group was treated with salmeterol without iCS and the second continued iCS therapy while randomized for salmeterol. In both groups Arg16 patients didn't draw benefit from salmeterol therapy comparing to Gly16 patients, which resulted in lower morning PEF, increased symptom scores and albuterol rescue use especially in trial without iCS. Present asthma treatment guidelines allow use of LABA only together with iCS since it has been demonstrated that iCS ameliorate the LABA effect. It is possible that in the future patients with Arg16Arg genotype will constitute a group requiring different treatment guidelines, but up to date therapeutic indications are uniform irrespective of the patient's genotype.

2.1.1.3 Correlation between β2-adrenoreceptor gene polymorphisms and asthma exacerbations

It has been proven that exacerbations of asthma during short acting β-agonist therapy is related to β2-adrenoreceptor gene polymorphisms (Taylor et al., 2000). Recent studies reveal, that children and adolescent asthmatics with the Arg16 genotype suffer from asthma exacerbations more frequently than the Gly16 subpopulation (OR 2.05, 95% CI 1.19 to 3.53, p=0.010). This genotype-exacerbation correlation significantly increases after salmeterol treatment (OR 3.40, 95% CI 1.19 to 9.40, p=0.022) (Palmer et al., 2006). Other studies confirm the conclusion that risk of asthma exacerbation in the Arg16 group rises with higher doses and more frequent use of β2-agonists. Individuals with the Arg16 genotype receiving short- or long-acting β2-agonists on everyday basis had significantly higher risk of asthma exacerbation (OR 1.64, 95% CI 1.22 to 2.20, p=0.001) than patients with the Arg16 genotype taking β2-agonist less than once daily (Basu et al., 2009). According to the LARGE study patients with the Gly16 genotype have diminished bronchial hyperresponsiveness to matacholine after adding inhaled corticosteroids (at an average dose 480μg of beclomethasone daily) to salmeterol treatment (Wechsler et al., 2009). Arg16 genotype Afro-Americans have a lower chance for lung function improvement after co-administration of LABA and inhaled corticosteroids what may be related to more frequent prevalence of Arg16 polymorphism in this population (25%). This can also explain ethnic differences in asthma manifestation – more frequent severe asthma occurrence in Afro-Americans. According to Liggett (Liggett, SB., 2000) β2-adrenoreceptors in Gly16 subjects are down regulated at baseline by exposure to endogenous cathecholamines what explains why reaction to exogenous β2-agonists is more evident in Arg16Arg individuals. At the same time however, Arg16 patients seem to have higher risk of asthma exacerbation especially

during β2-agonist therapy. Despite these differences present guidelines [GINA, BTS (British Thoracic Society)] do not recommend checking the patients' genotype before starting therapy. In our opinion LABA-treatment failure should be a recommendation for β2-adrenoreceptor genotype verification. This may increase both treatment effectiveness and safety. More research in this field is needed, however.

2.2 Pharmacogenetics of leukotriene modifiers

Leukotrienes are a family of polyunsaturated eicosatetraenoic acids that are derived from arachidonic acid in an enzymatic pathway called arachidonic acid cascade (see Figure 2.). In this pathway 5-lipoxygenase plays probably the most important role (Dixon et al., 1990). 5-lipoxygenase (5-LOX) catalyzes the conversion of arachidonic acid to leukotriene-A4 (LTA4) (Silverman & Drazen, 1999). All leukotrienes include cysteine and are called cysteinyl leukotrienes (with the exception of LTB4). Cysteinyl leukotrienes bind to CysLT1 receptor causing among others airway smooth muscle contraction, eosinophilic influx and mucus hypersecretion. Another important enzyme in the leukotriene pathway is LTC4 synthase, which is responsible for LTA4 to LTC4 conversion. Leukotrienes have been shown to be potent pro-inflammatory mediators in asthma pathology (Chanarin & Johnston, 1994). They are produced and released by several types of inflammatory cells including eosinophils, neutrophils and mast cells.



Fig. 2. The lipoxygenase pathway of leukotriene synthesis

Leukotriene modifiers are an important group of drugs in asthma treatment as well as in other diseases including allergic rhinitis. Based on their mode of action they can be divided into two groups: first – cysteine leukotrienes receptor antagonists (montelukast, zafirlukast, pranlukast and tomelukast), second - 5-lipoxygenase inhibitors (zileuton). These drugs show strong anti-inflammatory activity, ameliorate asthma clinical course and improve disease control with minimal or no side effects. Currently, they are listed in GINA 2010 (GINA, 2010) guidelines for asthma treatment as number two anti-inflammatory treatment (number one are still inhaled steroids), even though not all asthmatic patients benefit substantially from anti-leukotriene therapy. Based on the knowledge on leukotriene synthesis pathway, studies of genotype dependent therapeutic reactions have used strategies of candidate gene screening and examination of SNPs in genes encoding different proteins (enzymes) of the arachidonic acid cascade. To date, most investigations of the genetic factors which may affect therapy with anti-leukotriene drugs have focused on the 5-LOX enzyme and the LTC4 synthase. Possible genetic alterations of cysteine leukotriene receptors have also been investigated. The following paragraphs discuss the most important pharmacogenetic studies presenting major polymorphisms relevant in asthma and allergy as well as their impact on drug action.

2.2.1 Polymorphisms of the 5-lipoxygenase gene

The 5-LOX gene (ALOX5) is located on chromosome 10q11.12, contains 14 exons and its activity is associated with a number of repetitions of Sp1/Erg1 binding motifs in the promoter region (Hoshiko et al., 1990; Funk et al., 1989; Silverman et al., 1998). The promoter region containing five tandem motifs binding Sp1/Erg1 transcription factors (GGGCGG) is known as wild-type allele (Silverman et al., 1998). Polymorphisms of this region result from additions or deletions of binding motifs and are called non-wild-type alleles (In et al., 1997; Silverman et al., 1998). A polymorphism with one additional Sp1/Erg1 binding motif has been found in 35% of both asthmatic and non-asthmatic population (Fenech, A & Hall, IP., 2002). Further, 3% of the subjects without any copy of a wild-type allele are expected to have lower ALOX-5 gene transcription, which leads to reduced enzyme production and finally to lower LTA4 levels (Drazen et al., 1999; Kalayci et al., 2003). In consequence, the low level of cysteinyl leukotriene does not intensify allergic inflammation in asthma, but patients who do not have a wild-type allele, experience only 1% FEV1 improvement after 5-LOX inhibitor treatment comparing to wild-type patients (FEV1 improves up to 15-20%) and are considered non-responders for this type of therapy (Drazen et al., 1999). The same concerns to montelukast treatment (antagonist of cysteine leukotriene receptors): wild-type homozygous and heterozygous patients present benefit greatly from treatment (measured as FEV1 improvement (Telleria et al., 2008)), while non-wild-type are considered relative-non-responders. Other studies demonstrated however, that subjects with non-wild-type allele(s) treated with montelukast had reduced (73%) risk of asthma exacerbation (Lima et al., 2006). Because the role of leukotriene modifiers in asthma control increased significantly in the past five years, further studies are necessary to define responders and non-responders phenotypes. Defining standards of responding to leukotriene modifier therapy is extremely important at least in two subpopulations: in non-wild-type individuals, who in previous tudies have not experienced treatment benefit and in patient with steroid resistance or at least with partially impaired response to iCS.

2.2.2 Polymorphisms of the leukotriene C4 synthase gene (LTC4S)

LTC4 synthase (LTC4S) belongs to S-glutathione synthases family and is responsible for leukotriene A4 and glutathione bonding. This reaction results in leukotriene C4 synthesis. LTC4 is a potent contractor of bronchial smooth muscles. The gene for LTC4 synthase is located on chromosome 5q35. In the promoter region of this gene several polymorphism have been described. One of the most important is substitution of nucleotide A by C in position 444 (-444A→C). The -444A→C SNP results in increased LTC4S gene transcription and therefore higher LTC4 level in eosinophils (Sampson et al., 2000; Sanak et al., 2000). This variant occurs more often in patients suffering from aspirin induced asthma (in patients with aspirin idiosyncrasy in general) (Sanak et al., 1997). Presence of the C nucleotide is also related to better response to cysteine leukotriene receptor 1 (LTRA1) blockers. During montelukast therapy 80% reduction of asthma exacerbation risk was observed in heterozygous individuals with C allele when compared to AA homozygous (Lima et al., 2006). Similar results were reported from a study in Japan, where patients with moderate, well controlled asthma, treated with inhaled corticosteroids, received pranlukast as an add-on treatment. Again, individuals with the C allele had more pronounced FEV1 improvement than AA homozygous patients (FEV1 improvement in C allele group 5.3% vs. in AA group 2.4%). Heterozygous population also showed higher values of bronchial dilatation after salbutamol usage (Asano et al., 2002).

2.2.3 Polymorphisms of the cysteine leukotriene receptors 1 and 2 genes (CYSTLTR1, CYSTLTR2)

The human CYSLT1 and CYSLT2 receptors have been characterized as G-protein coupled receptors (Lynch et al., 1999; Heise et al., 2000). The gene coding for the CYSLT1 receptor is located on chromosome X and the CYSTLT2 receptor gene maps to chromosome 13q14 (Lynch et al., 1999; Heise et al., 2000). Polymorphisms of these genes are studied in relation to the probability of asthma development. Previous data suggest however, that polymorphisms of CYSTLTR1 and CYSTLTR2 genes play a minor role in the determination of asthma severity and clinical symptoms' expression (alike other genes encoding proteins related to leukotriene pathway) (Tantisira & Drazen, 2009). As for now there are no unequivocal results concerning polymorphisms of the CYSLT receptor genes in relation to anti-leukotriene treatment effects.

Although zileuton does not directly act through the CYSLT1 receptor, the possible correlation between this medication and CYSLT1R polymorphisms was also investigated. These studies, including genotype analysis of over five hundred patients treated with zileuton did not show any significant correlation between CYSLT1R gene polymorphisms and clinical response to therapy (Tantisira et al., 2009).

2.2.4 Polymorphisms of the ABCC1 gene

The ABCC1 gene (ATP-binding cassette, subfamily C, member 1) encodes MRP1 (Multiple Drug Resistance Protein 1) that takes a part in transmembrane LTC4 transport. This gene is located on chromosome 16p13.12 and demonstrates significant heterogeneity (Saito et al., 2002; van der Deen et al., 2005). One of the polymorphisms of this gene, that was thought to be correlated to drug response, namely rs119774, described by Lima et al. was related to a

significant FEV1 improvement in subjects receiving montelukast for 6 months (Lima et al., 2006). Heterozygous patients had a 24% FEV1 rise as compared to only a 2% improvement in homozygous individuals (Lima et al., 2006). Since there are no further studies of this correlation available data are insufficient to have any treatment implications. Again, further studies would help to elucidate whether the two phenotypes differ enough to justify different treatment regimens.

2.2.5 Polymorphism of LTA4 hydrolase gene

Hydrolase LTA4 is an enzyme that converts LTA4 to LTB4. The gene encoding this protein is located on chromosome 12q22. One of the known polymorphisms for this gene (rs2660845) involves a nucleotide change A->G at intron. Patients, whose genotypes contain at least one G allele (heterozygous), when treated with montelukast, have 4-5 higher risk of asthma exacerbation when compared to AA homozygous subjects (Lima et al., 2006). The pathogenetic mechanism of this phenomenon remains unclear. It has been hypothesized that this SNP causes a decreased enzyme activity that results in diminished LTB4 synthesis, therefore stimulating the LTC4-synthase pathway and leading to cysteine leukotriene synthesis (Lima et al., 2006) (Fig. 2).

There are big individual differences in response to leukotriene modifiers. All polymorphisms listed in paragraph 2.2 contribute to these differences. It remains extremely important to determine which patient subpopulation benefit most from the treatment.

2.2.6 Polymorphisms of the SLCO2B1 gene

The gene SLCO2B1 (solute carrier organic anion transporter family - 2B1) encodes the protein 2B1, that plays an important role in the active transport of organic anions through the intestinal wall. Protein 2B1 is thought to be a key transporter of montelukast through the intestinal wall. A recently described, common, SLCO2B1 polymorphism, namely rs12422149 935G→A (Arg312Gln), appears to relate to changes in montelukast pharmacokinetics. Specifically, individuals with this SNP have a significantly lower serum drug concentration (Mougey et al., 2009). So far, there are no data on other possible SLCO2B1 gene polymorphisms that could affect montelukast transport or serum level.

Gene	**Chromosomal location**	**Polymorphisms with potential pharmacogenetic consequences during leukotriene modifier therapy**
ALOX5	10q11.12	Promoter Sp1/Egr1binding motif (G+C rich sequence, i.e. –GGGCGG-) different than 5 sequence repeats, -212 to -88 bp
LTC4S	5q35	Promoter -444A→C
CYSLTR1	Xq13.2-q21.1	927C→T
ABCC1	16p13.12	rs119774, G→A intron
LTA4H	12q22	rs2660845, A→G intron
SLCO2B1	11q13	rs12422149 935G→A

Table 1. Genes polymorphisms with potential pharmacogenetic consequences for leukotriene modifier therapy

Leukotriene modifiers are widely used in asthma treatment and they are orally administered which improves patients compliance and therefore efficacy. However, genes linked to their metabolism, drug-receptor interactions etc. have not intensively investigated. In our opinion, cytochrome P450, that metabolises both groups of leukotriene modifiers (especially CYP1A2 and CYP3A4), is a promising target. Studies investigating genetic variants of cytochrome P450 enzymes in relation to leukotriene modifiers response are necessary to establish possible dosing variations.

2.3 Pharmacogenetics of inhaled corticosteroids (iCS)

Corticosteroids are the most important and the most effective medication in asthma therapy. They are powerful anti-inflammatory agents in asthma management, mostly being "anti-eosinophilic". Although many asthmatics derive therapeutic benefit from inhaled corticosteroids, many fail to respond or at least need to be treated with much higher doses. Despite iCS being considered a safe treatment, side effects of increased dosage may be clinically significant and include: adrenal suppression, osteoporosis, skin changes, cataract, and growth retardation in children. There at least two different mechanisms of CS resistance, but both are still under investigation.

Candidate gene studies were used to determine the pharmacogenetics of response to inhaled corticosteroids.

2.3.1 Glucocorticoid receptor

Corticosteroids exert their action by binding to the glucocorticoid intracellular receptor (GR), a nuclear receptor. The GR gene is located on the long arm of chromosome 5 (5q31-32). Members of the superfamily of nuclear receptors share a structural pattern containing a short central DNA-binding domain, a variable N-terminal domain as well as a C-terminal, which is the steroid hormone binding part, and a transcription regulator (Beato et al., 1996; Gronemeyer, 1992). There are two different GR isoforms known: one consisting of 777 (called GRα) and the other of 742 amino acids called GRβ. These isoforms are created during alternative splicing of the GR pre-mRNA (Bamberger et al., 1996). GRβ varies from the other isoform only in the length of C-terminal domain, which is shorter by five amino acids. This results in reduced glucocorticoid binding affinity of the GRβ receptor. Both receptors are expressed in all human cells, but GRβ plays a regulatory role and its concentration is much lower than that of GRα. Although there is no evidence to support that this polymorphism is responsible for reduced responsiveness to GC in clinical practice, this concept has been widely discussed and related studies are currently carried out (Brogan et al., 1999; Gagliardo et al., 2000; Malmstrom et al., 1999). In the cytoplasm, the glucocorticoid receptor is linked with several regulatory proteins, with the heat shock protein (hsp90), p59 immunophilin and p23 phosphoprotein being the most important (Smith & Toft, 1993). GR and hsp90 coupling enables ligand (CS) binding to the receptor and facilitates correct receptor "maturation" after synthesis (Smith & Toft, 1993). After CS binding the complex GR/hsp90 is disunited and activated GR/CS translocates to the nucleus and binds to DNA via the central domain consisting of two "zinc fingers"(Mitchell & Tjian, 1989). On the DNA side the fragment interacting with GR is called GRE (glucocorticoid response elements). This is one of the two mechanisms for CS to stimulate or inhibit transcription and therefore mRNA

synthesis. The other mechanism involves intra-cytoplasmic interaction of GR/CS with transcription factors, resulting in the blockage of their activity and consequently hampering transcription of several inflammatory agents as cytokines and chemokines, simplifying synthesis of anti-inflammatory agents (Barnes, 1996).

The importance of iCS in asthma treatment made the glucocorticoid receptors gene polymorphisms the obvious target of pharmacogenetic studies. However, despite the large number of researchers involved and the considerable funds devoted by both academic and industrial teams, only few polymorphisms have been discovered until now: Val→Asp641, that results in a three-fold lower binding affinity for dexamethasone, Val→Ile729 - with four-fold decrease in dexamethasone activity and Asn→Ser363 that results in higher activity to exogenous corticosteroids (Hurley et al., 1991; Malchof et al., 1993; Huizenga et al., 1998). From published studies we know, that patients with GR gene polymorphisms Val→Asp641 and Val→Ile729 may be predisposed to a relatively decreased response to CS therapy (Koper et al., 1997; Lane et al., 1994). A three marker long haplotype G-A-T (frequency 23% in general population; G allele - BclI SNP, A allele - intron B 33389, T allele - intron B 33388) was described in 2004 by Stevens and coworkers. It is associated with enhanced GC sensitivity measured as low postdexamethasone cortisol (frequency 41%). Subjects homozygous for G-A-T had over twofold FEV1 improvement after CS treatment compared to heterozygous or non-G-A-T haplotypes (Tantisira et al., 2004).

However, all these studies have not demonstrated a correlation between GR polymorphisms and corticosteroid resistance in asthma. Corticosteroid resistance does not seem to be dependent on a single GR gene polymorphism.

2.3.2 Polymorphisms of the CRHR1 gene (corticotropin releasing hormone receptor type 1)

In contrast to the GR gene polymorphism studies, CRHR1 investigations seem to yield more promising results. The CRHR1 gene is the major receptor for corticotropin that in turn is the key regulator of corticosteroids synthesis and catecholamine production. The gene for CRHR1 is located on chromosome 17q12-22, in the genomic region linked to asthma in a genome-wide-screen (Zandi et al., 2001). Most important data came from studies by Tantisira et al (Tantisira et al., 2004) that analyzed 14 genes connected with biological pathways of corticosteroids in three large groups of patients. Study participants were recruited from several other clinical trials studying the use of inhaled corticosteroids in asthma. The first group consisted of 470 adult individuals and was encoded AD (Adult Study), the second included 336 adult patients - ACRN (Asthma Clinical Research Network), and the third one included 311 children from CAMP (Childhood Asthma Management Program). This project revealed a significant correlation between lung function improvement after inhaled corticosteroid therapy and SNPs (rs1876828, rs242939 and rs242941) and haplotype occurrence within the CRHR1 gene, especially rs242941 (G→T, intron located) polymorphism, in all populations. In the AD population homozygous individuals with this polymorphism had average FEV1 improvement, higher than homozygous patients lacking this SNP. Similar results were obtained for the paediatric population that was studied. These data can contribute to our

understanding of the diverse patient reactions to iCS treatment but further investigation is still necessary.

2.3.3 Polymorphisms of the TBX21 gene (T-box expressed in T cells)

Another gene modulating inhaled corticosteroids action is TBX21 that encodes T-bet transcription factor (Tantisira et al., 2004). It plays an important role in balancing lymphocyte subpopulations, enhancing Th1 and inhibiting Th2 clone formation. TBX21 knockout mice develop bronchial hyperresponsiveness, enhanced airway eosinophilia and faster airway remodelling (Finotto et al., 2002) proving that TBX21 is crucial for asthma protection.

So far one clinically important SNP, His→Glu33 (H33Q), was found within this gene's area in mice. Cellular models suggest that the H33Q allele can activate Th1 cytokine production (including interferon γ – INFγ) that in turn decreases Th2 cytokine synthesis providing a stable protection against asthma and allergy development. Surprisingly enough, it has been demonstrated that corticosteroids are able to inhibit T-bet induction (Refojo et al., 2003) resulting in Th2 domination. These findings still require a direct in vivo confirmation.

Studies in children (CAMP population) showed 4.5% occurrence in general population of homozygous Glu33 individuals. The presence of even one copy of this allele in subjects treated with iCS was associated with a significant decrease in airway hyperresponsiveness (measured as PC20) as compared to His33His homozygous subjects and individuals not iCS-treated (Tantisira et al., 2004).

2.3.4 Polymorphisms of the FCER2 gene (Fc fragment of IgE, low affinity II, receptor for (CD23))

The FCER2 gene encodes a protein, which is the low-affinity receptor for IgE and a key molecule for B-cell activation and growth. FCER2 gene polymorphism was predicted to bronchial hypperresponsiveness and IgE-mediated allergic diseases. Within this gene three SNPs have been described, all connected to higher risk of severe asthma and asthma exacerbations in spite of inhaled corticosteroids therapy. The polymorphism 2206T→C occurs relatively often (allelic frequency 0.26 in Caucasians and 0.44 in black population) and was carefully analyzed for potential association to inhaled corticosteroids therapy response (Tantisira et al., 2007). The presence of the C allele increases three- to four-fold the risk of severe asthma exacerbations. This effect was confirmed both in Afro-American and Caucasian individuals being under iCS therapy.

2.3.5 Polymorphism of AC9 gene (cyclase adenylate 9)

Although adenylate cyclase is activated via the β2-adrenoreceptor it may also influence inhaled corticosteroids reaction. Individuals carrying the polymorphism Ile→Met 772 demonstrate increased bronchial dilatation after SABA when treated with corticosteroids compared to wild-type individuals (isoleucine in 772 position) (Tantisira et al., 2005). This substitution results in a loss of function. Met772 has lower basic as well as beta2-mediated adenylyl cyclase activities compared to Ile772.

Gene	Chromosomal location	Polymorphism with potential pharmacogenetic consequences during iCS therapy
CRHR1	17q12-22	rs242941 (G→T, intron)
TBX21	17q21.32	His→Glu33 (H33Q)
FCER2	19p13.3	2206T→C
AC9	16p13.3-13.2	Ile→Met 772

Table 2. List of gene polymorphism examples that could have pharmacogenetic consequences during corticosteroids therapy

2.4 Pharmacogenetics of anticholinergic treatment

2.4.1 Polymorphisms of the muscarinic receptor

Anticholinergics are used mainly in chronic obstructive pulmonary disease (COPD) but sometimes also in asthma as second line bronchodilators. Anticholinergics are antagonists of muscarinic receptors: M1, M2 and M3. SNPs have been found in coding regions of M2 and M3 receptors (Fenech, 2001). The expression of M2 and M3 receptors is dependent on transcription regulation in the gene promoter region and polymorphisms have been demonstrated in both promoter regions (Fenech, 2004; Donfack, 2003). Furthermore different expression of M2 receptor may be related to various number of dinucleotide CA repetitions in gene promoter region. None of these changes has been investigated in relation to bronchodilation in asthma or COPD yet.

3. Conclusions

Genome analysis, candidate gene studies and SNP investigation represent a new approach to pharmacological treatment in all chronic diseases. Genetically defined differences combined with clinical phenotyping lead to treatment personalization. At this point "personalization" means selecting different treatment regimens for different groups of patients. The more knowledge on pharmacogenetics and general genetics we have, the smaller these groups are likely to be.

iCS remain the mainstream therapy in asthma. Despite intensive research in this field there is only one biological treatment available for asthma and allergy (anti-IgE monoclonal antibody). Several other have been suggested and underwent pre-clinical or clinical tests, but to prove either their effectiveness and safety.

All the studies presented in this chapter have aimed at the identification and characterization of subgroups of asthmatic patients that will derive optimal therapy benefit while minimizing or eliminating drug side effects. The ultimate goal in the pharmacogenetics of antiasthmatic medication is to enable the optimization of individual therapies from the very start, maximizing efficacy without exposing patients to side effects. That would also significantly improve patient's treatment compliance. The amount of clear data from pharmacogenetics of antiasthmatic drugs is still limited due, among others, to the vast number of genotype variants in different populations.

Combined research of the past decade seem to suggests that either asthma has several phenotypes distinct in terms of inflammatory mechanisms (eosinophilic versus neutrophilic, IL-17 dependent vs non-dependent etc.) or "asthma" is rather a group of respiratory diseases with similar symptomatology than a uniform disease. Computerized multivariate analysis has to be employed in the process of defining clinically relevant disease phenotypes of asthma before effective pharmacogenetic research can be undertaken.

4. References

Asano, K.; Shiomi, T.; Hasegawa, N.; Nakamura, H.; Kudo, H. & Matsuzaki, T. (2004) *Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma*. Pharmacogenetics, 12:565-70.

Bamberger, CM.; Schulte, HM. & Chrousos, GP. (1996). *Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids*. Endocrine Reviews, 17:245–61.

Barnes, PJ. (1996). *Mechanisms of action of glucocorticoids in asthma.* American journal of respiratory and critical care medicine, 154: S21–S26.

Basu, K.; Palmer, CN.; Tavendale, R.; Lipworth, BJ. & Mukhopadhyay, S. (2009). *Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol*. Journal of Allergy and Clinical Immunology, 124:1188-94.

Beato, M.; Chavez, S. & Truss, S. (1996). *Transcriptional regulation by steroid hormones*. Steroids, 61:240–51.

Brogan, IJ.; Murray, IA.; Cerillo, G.; Needham, M.; White, A. & Davis, JR.(1999*) Interaction of glucocorticoid receptor isoforms with transcription factors AP-1 and NF-kappaB: lack of effect of glucocorticoid receptor beta.* Molecular and Cellular Endocrinology, 157, 95–104.

Carroll, CL.; Stoltz, P.; Schramm, CM. & Zucker, AR. (2009*). Beta2-adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations*. Chest, 135:1186-92.

Chanarin, N. & Johnston, SL.(1994). *Leukotrienes as a target in asthma therapy*. Drugs, 47: 12–24.

Dixon, RA.; Diehl, RE. & Opas, E. (1990). *Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis.* Nature, 343: 282–284.

Dixon, RA.; Kobilka, BK.; Strader, DJ.;, Benovic, JL.; Dohlman, HG.& Frielle, T. (1986). *Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin.* Nature, 321:75-9.

Donfack, J.; Kogut, P.; Forsythe, S.; Solway, J.; Solway, J. & Ober, C. (2003). *Sequence variation in the promoter region of the cholinergic receptor muscarinic 3 gene and asthma and atopy.* Journal of Allergy and Clinnical Immunology, 111: 527-532.

Drazen, JM.; Yandava, CN.; Dube, L.; Szczerback, N.; Hippensteel, R.; Pillari, A. & Israel, E. (1999). *Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment*. Nature Genetics, 22, 168–170.

Fenech, AG. & Hall, IP. (2002). *Pharmacogenetics of asthma*. Journal of Clinical Pharmacology, 53, 3-15.

Fenech, AG., Ebejer MJ.; Felice, AE.; Ellul-Micallef, R. & Hall, IP. (2001). *Mutation screening of the muscarinic M2 and M3 receptor genes in normal and asthmatic subjects.* British Journal of Pharmacology, 133: 43-48.

Fenech, AG.; Billington, CK. & Swan, C. (2004). *Novel polymorphisms influencing transcription of the human CHRM2 gene in airway smooth muscle.* American Journal of Respiratory Cell and Molecular Biology, 30: 678-686.

Finotto, S.; Neurath, MF.; Glickman, JN.; Qin, S.; Lehr, HA.; Green, FH. & Ackerman, K. (2002). *Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet*. Science, 295, 336–368.

Funk, CD.; Hoshiko, S.; Matsumoto, T.; Radmark, O. & Samuelsson, B. (1989). *Characterization of the human 5-lipoxygenase gene.* Proceedings of the National Academy of Sciences, 86: 2587–2591.

Gagliardo, R.; Chanez, P.; Vignola, AM.; Bousquet, J.; Vachier, I.; Godard, P. & Bonsignore, G. (2000) *Glucocorticoid receptor alpha and beta in glucocorticoid dependent asthma.* American Journal of Respiratory and Critical Care Medicine, 162, 7–13.

GINA (Global Initiative for Asthma, updated 2010)

Green, SA.; Rathz, DA.; Schuster, AJ. & Liggett, SB. (2001). *The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s).* European Journal of Pharmacology, 421:141-7.

Green, SA.; Turki, J.; Bejarano, P.; Hall, IP. & Liggett, SB. (1995) *Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells.* American Journal of Respiratory Cell and Molecular Biology, 13, 25–33.

Green, SA.; Turki, J.; Innis, M. & Liggett, SB. (1994). *Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties.* Biochemistry, 33, 9414–9419.

Gronemeyer, H. (1992). *Control of transcription activation by steroid hormone receptors*. FASEB Journal, 6:2524–9.

Heise, CE.; O'Dowd, BF. & Figueroa, DJ. (2000). *Characterization of the human cysteinyl leukotriene 2 receptor.* Journal of Biological Chemistry, 275: 30531–30536.

Hoshiko, S.; Radmark, O. & Samuelsson, B. (1990). Characterization *of the human 5-lipoxygenase gene promoter.* Proceedings of the National Academy of Sciences, 87: 9073–9077.

Huizenga, NA.; De Koper, JW. & Lange, P. (1998). *A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo.* The Journal of Clinical Endocrinology and Metabolism, 83: 144–151.

Hurley, DM.; Accili, D. & Stratakis, CA. (1991). *Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance.* Journal of Clinical Investigation, 87: 680–686.

In, KH.; Asano, K.; Beier, D.; Grobholz, J.; Finn, PW.; Silverman, EK. & Silverman, ES. (1997). *Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription.* Journal of Clinical Investigation, 99, 1130–1137.

Israel, E.; Chinchilli, VM.; Ford, JG.; Boushey, HA.; Cherniack, R. & Craig, TJ. (2004). *Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial.* Lancet, 364:1505-12.

Israel, E.; Drazen, JM.; Liggett, SB.; Boushey, HA.; Cherniack, RM. & Chinchilli, VM. (2000). *The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.* American Journal of Respiratory and Critical Care Medicine, 162:75-80.

Kalayci, O.; Wechsler, M.; Galper, B.; Hong, C.; Israel, E.; Drazen, JM. & Lilly, CM. (2003). *LTC4 production by eosinophils in asthmatic subjects with alternative forms of ALOX-5 core promoter*. Advances in Experimental Medicine and Biology, 525, 11–14.

Kazani, S.; Wechsler, ME. & Israel, E. (2010). *The role of pharmacogenomics in improving the management of asthma.* Journal of Allergy and Clinical Immunology, 125: 295-302.

Klotsman, M.; York, TP.; Pillai, SG.; Vargas-Irwin, C.; Sharma, SS.; van den Oord, EJ. & Anderson, WH. (2007). *Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast.* Pharmacogenetics and Genomics, 17:189-96.

Kobilka, BK.; Dixon, RA. & Frielle, T. (1987). *cDNA for the human β2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor*. Proceedings of the National Academy of Sciences, 84: 46–50.

Koper, JW.; De Stolk, RP. & Lange, P. (1997). *Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance.* Human Genetics, 99: 663–668.

Kowalski, ML. & Woszczek, G. (2002). *Pharmacogenetics of β2-adrenoreceptor and asthmatic phenotypes*. New trends in Allergy V. Springer-Verlag. Berlin Heidelberg, Germany; 13-20.

Lane, SJ.; Arm, JP.; Staynov, DZ. & Lee, TH. (1994). *Chemical mutational analysis of the human glucocorticoid receptor cDNA in glucocorticoid-resistant bronchial asthma. American Journal of Respiratory Cell and Molecular Biology*, 11: 42–48.

Lee, DK.; Currie, GP.; Hall, IP.; Lima, JJ. & Lipworth, BJ. (2004). *The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol.* British Journal of Clinical Pharmacology, 57:68-75.

Liggett, SB. (1997). *Polymorphisms of the β_2-adrenergic receptor and asthma*. American Journal of Respiratory and Critical Care Medicine, 156: S156–S162.

Lima, JJ.; Zhang, S.; Grant, A.; Shao, L.; Tantisira, KG. & Allayee, H.(2006*). Influence of leukotriene pathway polymorphisms on response to montelukast in asthma.* American Journal of Respiratory and Critical Care Medicine, 173:379-85.

Lipworth, BJ.; Hall, IP.; Tan, S.; Aziz, I. & Coutie, W. (1999). *Effects of genetic polymorphism on* ex vivo *and* in vivo *function of β2-adrenoceptors in asthmatic patients*. *Chest*, 115: 324–328.

Lynch, KR.; O'Neill, GP. & Liu, Q.(1999). *Characterization of the human cysteinyl leukotriene CysLT1 receptor.* Nature, 399: 789–793.

Malchoff, DM. Brufsky, A. & Reardon, G. (1993). *A mutation of the glucocorticoid receptor in primary cortisol resistance.* Journal of Clinical Investigation, 91: 1918–1925.

Malmstrom, K.; Rodriguez-Gomez, G.; Guerra, J.; Villaran, C.; Pineiro, A.; Wei, LX. & Seidenberg, BC. (1999). *Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial.* Montelukast/Beclomethasone Study Group. Annals of Internal Medicine, 130, 487–495.

Martinez, FD.; Graves, PE.; Baldini, M.; Solomon, S. & Erickson, R. *Association between genetic polymorphisms of the beta 2-adrenoceptor and response to albuterol in children with and without a history of wheezing.* Journal of Clinical Investigation, 100:3184-8.

Mitchell, PJ. & Tjian, R.(1989). *Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins.* Science,245:371–8.

Moffatt, MF. & Cookson, WO. (1997). *Linkage and candidate gene studies in asthma.* American Journal of Respiratory and Critical Care Medicine, 156: S110–S112.

Mougey, EB.; Feng, H.; Castro, M.; Irvin, CG. & Lima, JJ. (2009). *Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response*. Pharmacogenetics and Genomics, 19:129-38.

Nelson, HS.; Weiss, ST.; Bleecker, ER.; Yancey, SW. & Dorinsky, PM. (2006). *The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.* Chest, 129:15-26.

Palmer, CN.; Lipworth, BJ.; Lee, S.; Ismail, T.; Macgregor, DF. & Mukhopadhyay, S. (2006). *Arginine- 16 {beta}2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol*. Thorax, 61:940-4.

Refojo, D.; Liberman, AC.; Giacomini, D.; Carbia Nagashima, A.; Graciarena, M.; Echenique, C. & Paez Pereda, M. (2003). *Integrating systemic information at the molecular level: cross-talk between steroid receptors and cytokine signaling on different target cells.* Annals of the New York Academy of Science, 992, 196–204.

Saito, S.; Iida, A.; Sekine, A.; Miura, Y.; Ogawa, C.; Kawauchi, S.; Higuchi, S. & Nakamura, Y. (2002). *Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR).* Journal of Human Genetics, 47:147–171.

Sampson, AP.; Siddiqui, S.; Buchanan, D.; Howarth, PH.; Holgate, ST.& Holloway, JW. (2000). *Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast.* Thorax, 55(suppl 2): S28-31.

Sanak, M.; Pierzchalska, M.; Bazan-Socha, S. & Szczeklik, A. (2000). *Enhanced expression of the leukotriene C4 synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. American Journal of Respiratory Cell and Molecular Biology*, 23:290-6.

Sanak, M.; Simon, HU. & Szczeklik, A. (1997). *Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma.* Lancet, 350:1599–600.

Silverman, ES. & Drazen, JM. (1999). *The biology of 5-lipoxygenase: function, structure, and regulatory mechanisms.* Proceedings of the Association of American Physicians, 111, 525–536.

Silverman, ES.; In, KH.; Yandava, C. & Drazen, JM. (1998). *Pharmacogenetics of the 5-lipoxygenase pathway in asthma.* Clinical and Experimental Allergy, Suppl 5, 164–170.

Smith, DF. & Toft, DO. (1993). *Steroid receptors and their associated proteins.* Molecular Endocrinology, 7:4–11.

Stevens A.; Ray DW.; Zeggini E.; John E.; Richard HL.; Griffith CEM.; Donn R (2004) *Glucocorticoid sensitivity is determined by a specific glucocorticoid receptor haplotype.* The Journal of Clinical Endocrinology & Metabolism 89:892–897

Tan, S.; Hall, IP.; Dewar, J.; Dow, E. & Lipworth, B. (1997). *Association between β_2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics.* Lancet, 350: 995–999.

Tantisira, KG. & Drazen, JM. (2009). *Genetics and pharmacogenetics of the leukotriene pathway*. Journal of Allergy and Clinical Immunology, 124:422-7.

Tantisira, KG.; Hwang, ES. & Raby, BA. (2004). *TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids.* Proceedings of the National Academy of Sciences, 101:18099–18104.

Tantisira, KG.; Lake, S. & Silverman, ES. (2004) *Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids.* Human Molecular Genetics, 13:1353–1359.

Tantisira, KG.; Lima, J.; Sylvia, J.; Klanderman, B. & Weiss, ST. (2009). 5-*lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci.* Pharmacogenetics and Genomics, 19:244-7.

Tantisira, KG.; Silverman, ES.; Mariani, TJ.; Xu, J.; Richter, BG. &, Klanderman, BJ. (2007). *FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma.* Journal of Allergy Clinical Immunology, 120:1285-91.

Tantisira, KG.; Small, KM.; Litonjua, AA.; Weiss, ST. & Liggett, SB. (2005). *Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways.* Human Molecular Genetics, 14:1671-7.

Taylor, DR.; Drazen, JM.; Herbison, GP.; Yandava, CN.; Hancox, RJ. & Town, GI. (2000). *Asthma exacerbations during long term beta agonist use: influence of beta(2)adrenoceptor polymorphism*. Thorax, 55:762-7.

Telleria, JJ.; Blanco-Quiros, A.; Varillas, D.; Armentia, A.; Fernandez-Carvajal, I.; Jesus Alonso, M. & Diez, I. (2008). *ALOX5 promoter genotype and response to montelukast in moderate persistent asthma.* Respiratory Medicine,102:857-61.

van der Deen, M.; de Vries, EG.; Timens, W.; Scheper, RJ.; Timmer-Bosscha, H.& Postma, DS. (2005). *ATP-binding cassette (ABC) transporters in normal and pathological lung*. Respiratory Research, 6:59

Wechsler, ME.; Kunselman, SJ.; Chinchilli, VM.; Bleeker, E.; Boushey, HA. & Calhounb, WJ. (2009). *Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.* Lancet, 374:1754-64.

Wechsler, ME.; Lehman, E.; Lazarus, SC.; Lemanske, RF.; Boushey, HA. & Deykin, A. (2006). *beta-Adrenergic receptor polymorphisms and response to salmeterol.* American Journal of Respiratory and Critical Care Medicine, 173:519-26.

Weiss, ST.; Litonjua, AA.; Lange, C.; Lazarus, R.; Liggett, SB. & Bleecker, ER. (2006). *Overview of the pharmacogenetics of asthma treatment.* Pharmacogenomics Journal, 6: 311-26.

Woszczek, G.; Borowiec, M.; Ptasinska, A.; Kosinski, S.; Pawliczak, R. & Kowalski, ML. (2005). *Beta2-ADR haplotypes/polymorphisms associate with bronchodilator response and total IgE in grass allergy.* Allergy, 60:1412-7.

Xie HG.; Stein, CM.; Kim, RB.; Xiao, ZS.; He, N., Zhou, HH.; Gainer, JV., Brown, NJ.; Haines, JL. & Wood, AJ.. (2001). *Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals.* Pharmacogenetics, 11(2):185.

Zandi, PP.; Klein, AP.; Addington, AM.; Hetmanski, JB.; Roberts, L. & Peila, R. (2001). *Multilocus linkage analysis of the German asthma data. Genetics Epidemiology*, 21: S210–S215.

IntechOpen



Clinical Applications of Pharmacogenetics

Edited by Dr. Despina Sanoudou

ISBN 978-953-51-0389-9
Hard cover, 292 pages
Publisher InTech
Published online 21, March, 2012
Published in print edition March, 2012

The rapidly evolving field of Pharmacogenetics aims at identifying the genetic factors implicated in the inter-individual variation of drug response. These factors could enable patient sub-classification based on their treatment needs thus expediting drug development and promoting personalized, safer and more effective treatments. This book presents Pharmacogenetic examples from a broad spectrum of different drugs, for different diseases, which are representative of different stages of evaluation or application. It has been designed so as to serve both the unfamiliar reader through explanations of basic Pharmacogenetic concepts, the clinician with presentation of the latest developments and international guidelines, and the research scientist with examples of Pharmacogenetic applications, discussions on the limitations and an outlook on the new scientific trends in this field.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Andrzej Mariusz Fal and Marta Rosiek-Biegus (2012). Pharmacogenetics of Asthma, Clinical Applications of Pharmacogenetics, Dr. Despina Sanoudou (Ed.), ISBN: 978-953-51-0389-9, InTech, Available from: http://www.intechopen.com/books/clinical-applications-of-pharmacogenetics/pharmacogenetics-of-asthma

INTECH
open science | open minds

InTech Europe
University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen